Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations
TD Clay, PA Russell, H Do, V Sundararajan, M Conron, GM Wright, A Dobrovic, MM Moore, SA McLachlan
PATHOLOGY | ELSEVIER SCIENCE BV | Published : 2016
We sought to investigate the frequency of mutations in epidermal growth factor receptor (EGFR) and Kirsten-RAS (KRAS) by each pathological subtype for patients with resected pulmonary adenocarcinoma as defined by the IASLC/ATS/ERS classification. Histological examination determined the predominant subtype according to the IASLC/ATS/ERS classification. EGFR and KRAS mutations were determined by high-resolution melting and Sanger sequencing. Clinical data were collected from medical records and clinicians. The 178 consecutive patients consisted of 48% males, median age 68 years (range 20-87) and smoking history 78%. The tumour stage was I in 62%, II in 18% and III in 20%. The mutation rates we..View full abstract
Dr Clay declares previously receiving financial support to attend scientific meetings from Boehringer Ingelheim and Roche. All other authors state that they have no conflicts of interest to disclose.